{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:28:28Z","timestamp":1770751708904,"version":"3.50.0"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,6,23]],"date-time":"2009-06-23T00:00:00Z","timestamp":1245715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Scand J Immunol"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of this study was to evaluate the efficacy and safety of etanercept (ETA) for treating rheumatoid arthritis. A systematic review was performed to search for randomized clinical trials comparing subcutaneous doses of ETA at 25\u2003mg twice a week or 50\u2003mg weekly to a placebo group, with or without methotrexate. Studies of low quality (less than 3 points on Jadad\u2019s scale) were excluded. The efficacy was assessed by using the criteria of the American College of Rheumatology (ACR). Safety data were evaluated based on serious adverse events, serious infections, malignancy and deaths. Withdrawals as a result of adverse events or lack of efficacy were also evaluated. Eight studies met the inclusion criteria, comprising 2385 patients. In the efficacy meta\u2010analysis, a greater number of ETA\u2010treated patients achieved the efficacy criteria within 6\u2003months of treatment, where the relative risk (RR) was 2.94 [2.27, 3.81] for achieving ACR20, 5.28 [3.12, 8.92] for ACR50 and 4.83 [1.74, 13.47] for ACR70. After 1\u2003year, the RR for achieving ACR20, ACR50 and ACR70 were 1.14 [1.07, 1.23], 1.36 [1.21, 1.53] and 1.56 [1.30, 1.88], respectively. This response rates were higher for ETA\u2010treated patients in comparison with control group patients. For safety, there were no statistically significant differences between treated patients and controls. This was also confirmed by withdrawals as a result of adverse events, which were not statistically different between the two groups. However, more patients withdrew from control groups because of a lack of efficacy as compared with ETA groups (RR\u2003=\u20030.48 [0.30, 0.78]).<\/jats:p>","DOI":"10.1111\/j.1365-3083.2009.02296.x","type":"journal-article","created":{"date-parts":[[2009,6,23]],"date-time":"2009-06-23T14:15:59Z","timestamp":1245766559000},"page":"337-344","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["A Systematic Review and Meta\u2010analysis of the Efficacy and Safety of Etanercept for Treating Rheumatoid Arthritis"],"prefix":"10.1111","volume":"70","author":[{"given":"Astrid","family":"Wiens","sequence":"first","affiliation":[]},{"given":"Cassyano Januario","family":"Correr","sequence":"additional","affiliation":[]},{"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[]},{"given":"Rafael","family":"Venson","sequence":"additional","affiliation":[]},{"given":"Juliana Vasconcelos","family":"Quinalha","sequence":"additional","affiliation":[]},{"given":"Michel Fleith","family":"Otuki","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2009,9,8]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.049650"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15640-7"},{"key":"e_1_2_5_4_2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/ard.2007.076166","article-title":"The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy","volume":"67","author":"Van Der Heijde D","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.10.001"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-9-52"},{"key":"e_1_2_5_7_2","first-page":"231","article-title":"Health\u2010related quality of life in early rheumatoid arthritis: impact of disease and treatment response","volume":"8","author":"Kosinski M","year":"2002","journal-title":"Am J Manag Care"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0797"},{"key":"e_1_2_5_9_2","first-page":"151","article-title":"Atualiza\u00e7\u00e3o do consenso brasileiro no diagn\u00f3stico e tratamento da artrite reumat\u00f3ide","volume":"47","author":"B\u00e9rtolo MB","year":"2007","journal-title":"Rev Bras Reumatol"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.9.5575"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2005.02940.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1995.tb08340.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2005.02744.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432201"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00004"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61000-4"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20019"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2005.01570.x"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-007-0626-3"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1715"},{"key":"e_1_2_5_21_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/01.bor.0000198007.73320.6e","article-title":"Musculoskeletal manifestations and autoimmune diseases related to new biologic agents","volume":"18","author":"Haraoui B","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.3.278"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.47.0602"},{"key":"e_1_2_5_24_2","first-page":"471","article-title":"Sarcoidosis occuring during anti\u2010TNF\u2010alpha treatment for inflammatory rheumatic diseases: report of two cases","volume":"26","author":"Toussirot E","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_5_25_2","first-page":"234","article-title":"Improved health\u2010related quality of life with effective disease\u2010modifying antirheumatic drugs: evidence from randomized controlled trials","volume":"14","author":"Strand V","year":"2008","journal-title":"Am J Manag Care"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_5_28_2","unstructured":"Review Manager (RevMan)[Computer program]. Version 5.0.The Cochrane Collaboration. Copenhagen:The Nordic Cochrane Centre 2008."},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.034769"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1037\/1082-989X.11.2.193"},{"key":"e_1_2_5_31_2","first-page":"618","article-title":"A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12\u2010week, double\u2010blind, randomized, placebo\u2010controlled study","volume":"103","author":"Lan JL","year":"2004","journal-title":"J Formos Med Assoc"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/84.6.1463"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901283400401"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21655"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23141"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.009563"},{"key":"e_1_2_5_37_2","unstructured":"Administration FAD.Arthritis Drugs Advisory Committee: safety update on TNF antagonists: infliximab and etanercept.2006;http:\/\/wwwfdagov\/medwatch\/SAFETY\/2006\/May_PIs\/Remicade_PIpdfhttp:\/\/wwwfdagov\/medwatch\/SAFETY\/2006\/May_PIs\/Remicade_PIpdf."},{"key":"e_1_2_5_38_2","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004525","article-title":"Etanercept for the treatment of rheumatoid arthritis","author":"Blumenauer B","year":"2003","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Scandinavian Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-3083.2009.02296.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-3083.2009.02296.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T11:39:07Z","timestamp":1697283547000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-3083.2009.02296.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,8]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1111\/j.1365-3083.2009.02296.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-3083.2009.02296.x","archive":["Portico"],"relation":{},"ISSN":["0300-9475","1365-3083"],"issn-type":[{"value":"0300-9475","type":"print"},{"value":"1365-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,8]]},"assertion":[{"value":"2009-09-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}